2019.11
TWi successfully launches generic Metoprolol Succinate ER Tablets in TWi label

November 1, 2019. TWi Pharmaceuticals, Inc. announced the official launch of Metoprolol Succinate ER Tablets 25mg, 50mg, 100mg and 200mg (equivalent to Toprol-XL) via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc.

Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension. According to IQVIA data, the total sales of Metoprolol Succinate ER Tablets in the US were approximately US $554 million for the 12 months ended September 2019.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Top